Frequently reported ( in > @ % of patients ) grade @-@ adverse events with PAD induction , salvage ASCT , and cyclophosphamide were : neutropenia ( @ -LSB- @ % -RSB- of @ patients after PAD , and @ -LSB- @ % -RSB- of @ patients in the salvage ASCT group vs @ -LSB- @ % -RSB- of @ patients in the cyclophosphamide group ) , thrombocytopenia ( @ -LSB- @ % -RSB- after PAD , and @ -LSB- @ % -RSB- vs four -LSB- @ % -RSB- , respectively ) , and peripheral neuropathy ( @ -LSB- @ % -RSB- after PAD , and none vs none , respectively ) .